首页 产品中心
  • LFM-A13
    • LFMA13
    货号: abs810668
    CAS号: 244240-24-2
    分子式: C11H8Br2N2O2
    分子量: 360
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs810668-5mg 1-2周 ¥560.00
    - +
    abs810668-10mg 1-2周 ¥874.00
    - +
    abs810668-50mg 1-2周 ¥3335.00
    - +
    abs810668-100mg 1-2周 ¥6003.00
    - +
    大包装询价
    产品描述
    描述
    FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC??’s = 2.5 μM (recombinant BTK) and 17.2 μM (human BTK).
    纯度
    >98%
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    别名
    LFMA13
    外观
    Powder
    可溶性/溶解性
    DMSO 72 mg/mL warmed (200.0 mM)





    生物活性
    靶点
    BTK
    In vitro(体外研究)
    In BTK+ B-lineage leukemic cells, LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels In human neutrophils, LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity.
    In vivo(体内研究)
    In BALB/c mice bearing BCL-1 leukemia, combination of LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. In primary myeloma-bearing SCID-rab mice, LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要提问

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0